Benzoic acid compounds and use thereof as medicaments
    1.
    发明授权
    Benzoic acid compounds and use thereof as medicaments 失效
    苯甲酸化合物及其作为药物的用途

    公开(公告)号:US5864039A

    公开(公告)日:1999-01-26

    申请号:US982389

    申请日:1997-12-02

    IPC分类号: C07D221/02 C07D265/14

    CPC分类号: C07D221/02 C07D265/14

    摘要: Benzoic acid compounds of the formula ##STR1## wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention have high and selective affinity for serotonin 4 receptor, and show agonistic effects thereon. Accordingly, they are useful medications for the prophylaxis and treatment of various gastrointestinal diseases, central nervous disorders, cardiac function disorders, urinary diseases, and the like, as well as useful anti-nociceptors for analgesic use which increase threshold of pain.

    摘要翻译: 式(I)的苯甲酸化合物,其中每个符号如说明书中所定义,其光学异构体和其药学上可接受的盐; 包含该化合物和药学上可接受的添加剂的药物组合物; 和5-羟色胺4受体激动剂,胃肠促动素和各种胃肠道疾病的治疗剂,其包含该化合物作为活性成分。 本发明化合物对5-羟色胺4受体具有高选择性的亲和力,并且对其表现出激动作用。 因此,它们是用于预防和治疗各种胃肠道疾病,中枢神经障碍,心脏功能障碍,尿病等的有用药物,以及增加疼痛阈值的有用的止痛药用抗伤害感受器。

    Pharmaceutical use of pyridine compounds
    4.
    发明授权
    Pharmaceutical use of pyridine compounds 失效
    吡啶化合物的药用

    公开(公告)号:US5616581A

    公开(公告)日:1997-04-01

    申请号:US460666

    申请日:1995-06-02

    摘要: A pyridine compound of the formula ##STR1## wherein R.sup.1 is a hydrogen, a halogen, an alkyl, an alkoxy or the like, R.sup.2 and R.sup.3 are each a hydrogen, a halogen or an alkyl, --P.dbd.Q-- is --CH.dbd.CH--, --N.dbd.CH-- or --CH.dbd.N--, A is an oxygen atom, a sulfur atom or N(R.sup.4) wherein R.sup.4 is hydrogen, alkyl or the like, n is 0, 1 or 2, B is S(O)p wherein p is 0, 1 or 2, D is a single bond, an alkylene or the like and E is an alkoxyalkyl or --N(R.sup.6)(R.sup.7), and a pharmaceutically acceptable salt thereof have antibacterial activity against Helicobacter pylori, antiulcer activity, gastrointestinal cytoprotective activity, ulcer recurrence, relapse-preventive activity and gastric acid secretion-suppressive activity and are useful as pharmaceutical preparations.

    摘要翻译: 式(I)的吡啶化合物其中R 1是氢,卤素,烷基,烷氧基等,R 2和R 3各自是氢,卤素或烷基,-P = Q-是 -CH = CH-,-N = CH-或-CH = N-,A是氧原子,硫原子或其中R4是氢,烷基等的N(R4),n是0,1或2, B是S(O)p,其中p是0,1或2,D是单键,亚烷基等,E是烷氧基烷基或-N(R6)(R7),其药学上可接受的盐具有抗菌性 针对幽门螺杆菌的活性,抗溃疡活性,胃肠细胞保护活性,溃疡复发,复发预防活性和胃酸分泌抑制活性,可用作药物制剂。

    Pyridine compound and pharmaceutical compostions
    5.
    发明授权
    Pyridine compound and pharmaceutical compostions 失效
    吡啶化合物和药物组合物

    公开(公告)号:US5504082A

    公开(公告)日:1996-04-02

    申请号:US352183

    申请日:1994-12-01

    摘要: A pyridine compound of the formula ##STR1## wherein R.sup.1 is a hydrogen, a halogen, an alkyl, an alkoxy or the like, R.sup.2 and R.sup.3 are each a hydrogen, a halogen or an alkyl, --P.dbd.Q-- is --CH.dbd.CH--, --N.dbd.CH-- or --CH.dbd.N--, A is an oxygen atom, a sulfur atom or N(R.sup.4) wherein R.sup.4 is hydrogen, alkyl or the like, n is 0, 1 or 2, B is S(O)p wherein p is 0, 1 or 2, D is a single bond, an alkylene or the like and E is an alkoxyalkyl or --N(R.sup.6)(R.sup.7), and a pharmaceutically acceptable salt thereof have antibacterial activity against Helicobater pylori, antiulcer activity, gastrointestinal cytoprotective activity, ulcer recurrence, relapse-preventive activity and gastric acid secretion-suppressive activity and are useful as pharmaceutical preparations.

    摘要翻译: 式(I)的吡啶化合物其中R 1是氢,卤素,烷基,烷氧基等,R 2和R 3各自是氢,卤素或烷基,-P = Q-是 -CH = CH-,-N = CH-或-CH = N-,A是氧原子,硫原子或其中R4是氢,烷基等的N(R4),n是0,1或2, B是S(O)p,其中p是0,1或2,D是单键,亚烷基等,E是烷氧基烷基或-N(R6)(R7),其药学上可接受的盐具有抗菌性 针对幽门螺旋杆菌的活性,抗溃疡活性,胃肠细胞保护活性,溃疡复发,复发预防活性和胃酸分泌抑制活性,可用作药物制剂。

    Benzazine compounds and pharmaceutical uses thereof
    8.
    发明授权
    Benzazine compounds and pharmaceutical uses thereof 失效
    苯并嗪化合物及其药物用途

    公开(公告)号:US5185333A

    公开(公告)日:1993-02-09

    申请号:US721011

    申请日:1991-06-26

    摘要: A benzazine compound, a geometrical isomer of said benzazine compound, an optical isomer of said benzazine compound, and a pharmaceutically acceptable salt of said benzazine compound, said benzazine compound being represented by formula (I): ##STR1## wherein each symbol is as defined in the specification. Said benzazine compounds exhibit 5-HT.sub.3 receptor antagonistic activity, and 5-HT.sub.1A receptor and/or 5-HT.sub.2 receptor and/or dopamine D.sub.2 receptor blocking activity so that they are useful as drugs for the prophylaxis or treatment of various digestive diseases vomiting and disturbances in central nervous systems and the like. The intermediates for said benzazine compounds are also disclosed.

    摘要翻译: 苯并嗪化合物,所述苯并嗪化合物的几何异构体,所述苯并嗪化合物的光学异构体和所述苯并嗪化合物的药学上可接受的盐,所述苯并嗪化合物由式(I)表示:其中每个符号 如本说明书中所定义。 所述苯并嗪化合物显示5-HT 3受体拮抗活性和5-HT1A受体和/或5-HT2受体和/或多巴胺D2受体阻断活性,使得它们可用作预防或治疗各种消化疾病呕吐和干扰的药物 在中枢神经系统等中。 还公开了所述苯并嗪化合物的中间体。